# OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

> **NCT00382811** · PHASE3 · COMPLETED · sponsor: **MEI Pharma, Inc.** · enrollment: 142 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Peritoneal Neoplasms
- Ovarian Cancer

## Interventions

- **DRUG:** phenoxodiol
- **DRUG:** carboplatin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00382811
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-04
- **Final completion:** 2011-04
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00382811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00382811, "OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00382811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*